Could a Triple-Drug cocktail beat long COVID?

NCT ID NCT07597902

Not yet recruiting Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of three drugs—valacyclovir, celecoxib, and Paxlovid—can reduce Long COVID symptoms in adults. About 150 participants aged 18-65 with diagnosed Long COVID will receive either the drug combo or a placebo. The main goal is to see if the treatment improves self-rated health and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: combination of valacyclovir, celecoxib, and Paxlovid
What this could lead to: If it works, this could point toward a treatment that eases Long COVID symptoms and improves quality of life.
What could go wrong: This is a small, early-phase trial with only 150 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID POST ACUTE SEQUELAE OF COVID-19

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)

New York, New York, 10029, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.